Stockscreener 앱 받기
11.38
0.09%
-0.010
시간 외 거래:
11.43
0.05
+0.44%
전일 마감가:
$11.39
열려 있는:
$11.3
하루 거래량:
2.08M
Relative Volume:
1.31
시가총액:
$1.25B
수익:
$-249.00K
순이익/손실:
$-187.60M
주가수익비율:
-4.552
EPS:
-2.5
순현금흐름:
$-201.88M
1주 성능:
-5.17%
1개월 성능:
-19.86%
6개월 성능:
+80.63%
1년 성능:
+190.31%
1일 변동 폭
$10.88
$11.42
1주일 범위
$10.83
$12.19
52주 변동 폭
$2.865
$16.96
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
명칭
Amylyx Pharmaceuticals Inc
전화
617-683-0917
주소
43 THORNDIKE STREET, CAMBRIDGE
AMLX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMLX
Amylyx Pharmaceuticals Inc
|
11.38 | 1.25B | -249.00K | -187.60M | -201.88M | -2.50 |
|
ZTS
Zoetis Inc
|
129.35 | 57.01B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.79 | 49.57B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.11 | 35.57B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
502.71 | 21.08B | 3.08B | 1.24B | 1.07B | 25.61 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Guggenheim | Buy |
| 2025-06-17 | 개시 | Citigroup | Buy |
| 2025-05-30 | 개시 | TD Cowen | Buy |
| 2025-04-07 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2024-11-18 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-10-23 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-03-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2024-03-11 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-03-11 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-03-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-03 | 개시 | Robert W. Baird | Outperform |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-07-24 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-03-31 | 개시 | Mizuho | Buy |
| 2023-01-05 | 개시 | BofA Securities | Buy |
| 2022-05-25 | 개시 | Citigroup | Buy |
| 2022-04-01 | 다운그레이드 | Goldman | Buy → Neutral |
모두보기
Amylyx Pharmaceuticals Inc 주식(AMLX)의 최신 뉴스
Amylyx Pharmaceuticals pushes for novel therapy development - Traders Union
Relative Strength Alert For Amylyx Pharmaceuticals - Nasdaq
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase and Clinical Data - Quiver Quantitative
Amylyx Pharmaceuticals (NASDAQ:AMLX) Trading Down 7.2%Time to Sell? - MarketBeat
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Guidance Update: What margin trends mean for Amylyx Pharmaceuticals Inc stockPortfolio Return Summary & Daily Oversold Bounce Ideas - moha.gov.vn
Hedge Fund and Insider Trading News: Ken Griffin, Ray Dalio, Warren Buffett, Toms Capital, Ken Fisher, Pershing Square, Amylyx Pharmaceuticals Inc (AMLX), NVIDIA Corp (NVDA), and More - Insider Monkey
Amylyx Pharmaceuticals Stock (AMLX) Opinions on Insider Purchase - Quiver Quantitative
Amylyx announces proposed public offering of common stock - MSN
How Investors Are Reacting To Amylyx Pharmaceuticals (AMLX) Early AMX0114 Safety Data And Insider Buying - Sahm
Amylyx Pharma director Firestone buys $100k in AMLX stock By Investing.com - Investing.com UK
Amylyx Pharma director Firestone buys $100k in AMLX stock - Investing.com
Amylyx Pharmaceuticals (NASDAQ:AMLX) Director Acquires $100,845.00 in Stock - MarketBeat
Amylyx Pharmaceuticals Director Karen Firestone Acquires 8,100 Shares - TradingView — Track All Markets
Will Amylyx Pharmaceuticals Inc. stock deliver long term returnsEvening Star Patterns & Free Rapid Return Acceleration - Bollywood Helpline
How Amylyx Pharmaceuticals Inc. stock trades before earningsLayoff News & Verified Momentum Watchlists - Улправда
Will Amylyx Pharmaceuticals Inc. stock recover faster than peers2025 Key Lessons & Real-Time Chart Pattern Alerts - Улправда
Amylyx Pharmaceuticals (NASDAQ:AMLX) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Will Amylyx Pharmaceuticals Inc. stock return to pre crisis levelsBull Run & Expert Approved Momentum Trade Ideas - Улправда
Will Amylyx Pharmaceuticals Inc. stock benefit from sector rotation2025 Institutional Moves & Stock Timing and Entry Methods - Улправда
Is Amylyx Pharmaceuticals Inc. stock recession proofTrade Risk Report & High Conviction Buy Zone Alerts - DonanımHaber
What margin trends mean for Amylyx Pharmaceuticals Inc. stockMarket Activity Summary & High Conviction Buy Zone Picks - DonanımHaber
Is Amylyx Pharmaceuticals Inc. stock trading at a premium valuationEarnings Summary Report & Weekly Sector Rotation Insights - ulpravda.ru
AMLX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class ActionAMLX - TMX Newsfile
Amylyx Pharmaceuticals Earnings Notes - Trefis
TFG Asset Management GP Ltd Makes New $1.40 Million Investment in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
683 Capital Management LLC Has $13.85 Million Stake in Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
ALS medication AMX0114 shows safety, moves to 2nd trial group - ALS News Today
Amylyx Pharmaceuticals (AMLX) Price Target Increased by 12.96% to 20.74 - MSN
Amylyx pins its next hopes on a niche drug in the obesity space - Pharma Voice
Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? - Yahoo Finance
Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge? - Sahm
Amylyx presents safety outcomes of AMX0114 in LUMINA study - MSN
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? - Nasdaq
Amylyx Pharmaceuticals Inc (AMLX) Receives a Buy from Mizuho Securities - The Globe and Mail
Rare Disease Leaders Call for Regulatory Consistency After Chaotic Year - BioSpace
Amylyx’s ALS drug AMX0114 shows positive early safety data By Investing.com - Investing.com Nigeria
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Positive Buy Rating for Amylyx Pharmaceuticals Based on Promising Phase I LUMINA Study Results and Strategic Advancements - TipRanks
Presentation at MNDA: Characterizing the CSF Biomarker Signature of Calpain-2 Activity in ALS and Its Application in the Phase 1 LUMINA Trial (dae63b) - marketscreener.com
Amylyx’s ALS drug AMX0114 shows positive early safety data - Investing.com India
Amylyx Pharmaceuticals announces new safety and tolerability cohort 1 data of amx0114 - marketscreener.com
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial - Business Wire
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Increased by Saturn V Capital Management LP - MarketBeat
Amylyx Pharmaceuticals, Inc. $AMLX Stock Position Lifted by Alpha Wave Global LP - MarketBeat
Can Amylyx Pharmaceuticals Inc. stock sustain revenue growthJuly 2025 Spike Watch & Long-Term Safe Return Strategies - Newser
Camille Bedrosian Sells 6,580 Shares of Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock - MarketBeat
Geode Capital Management LLC Acquires 886,252 Shares of Amylyx Pharmaceuticals, Inc. $AMLX - MarketBeat
Top Executive Makes Significant Stock Sale at Amylyx Pharmaceuticals - TipRanks
Transcript : Amylyx Pharmaceuticals, Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 04 - marketscreener.com
Amylyx Pharmaceuticals CMO Sells Shares to Cover Tax Obligations - TradingView
Amylyx Pharmaceuticals Inc (AMLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Amylyx Pharmaceuticals Inc 주식 (AMLX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bedrosian Camille L | Chief Medical Officer |
Dec 01 '25 |
Sale |
14.35 |
6,580 |
94,418 |
175,756 |
0.29%
자본화:
|
볼륨(24시간):